52 results
8-K
EX-99.2
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
9:02am
leads to impaired psychosocial development, education, and employment, and often results in permanent disability and increased mortality4 1. Black J, et
8-K
EX-99.2
AXSM
Axsome Therapeutics Inc
7 Dec 23
Other Events
4:05pm
; Loss of ‘sparkle’ Non-Stimulants Low effect sizes for all Clonidine and guanfacine: sedation, lack of data in adults with ADHD Atomoxetine: black box … (65.5) 43 (72.9) Black or African American 4 (13.3) 8 (27.6) 12 (20.3) Asian 1 (3.3) 2 (6.9) 3 (5.1) Unknown 1 (3.3) 0 1 (1.7) Body mass index (kg/m2
8-K
EX-99.1
4ahqkt7 h555ns
8 Sep 22
Other Events
4:06pm
8-K
EX-99.1
wz1qj5x8pe7
28 Jun 22
Other Events
5:18pm